Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients

Clin Appl Thromb Hemost. 2003 Apr;9(2):173-4. doi: 10.1177/107602960300900215.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / drug therapy
  • Anemia / etiology
  • Biomarkers / analysis
  • Blood Proteins / analysis
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / epidemiology
  • Comorbidity
  • Endothelium, Vascular / injuries
  • Erythropoietin / administration & dosage
  • Erythropoietin / pharmacology*
  • Erythropoietin / therapeutic use
  • Follow-Up Studies
  • Humans
  • Injections, Subcutaneous
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / epidemiology
  • Kidney Failure, Chronic / therapy
  • Lipoproteins / analysis*
  • Recombinant Proteins
  • Renal Dialysis
  • Thromboplastin / analysis*

Substances

  • Biomarkers
  • Blood Proteins
  • Lipoproteins
  • Recombinant Proteins
  • lipoprotein-associated coagulation inhibitor
  • Erythropoietin
  • Thromboplastin